Tresiba Cost in Florida: Insulin Degludec Prices, Insurance, and Savings

What Tresiba is, and why "the cost" is not one number

Tresiba is Novo Nordisk's brand name for insulin degludec, an ultra-long-acting basal insulin approved by the FDA in 2015 and available as U-100 and U-200 FlexTouch pens for once-daily subcutaneous injection. It is a distinct molecule from insulin glargine (sold as Lantus, Basaglar, Rezvoglar, or Toujeo) and from rapid-acting insulins such as lispro or aspart. It is not a GLP-1 receptor agonist and is not related to semaglutide or tirzepatide, despite sometimes appearing alongside those drugs in diabetes-cost searches.

Florida has a large population of adults living with diagnosed diabetes, and the Centers for Disease Control and Prevention publishes state-level diabetes prevalence data that readers can check directly rather than relying on a single fixed number here, since surveillance figures update over time. [1]

For a Florida patient, "how much does Tresiba cost" really splits into four separate questions: what does Novo Nordisk charge before any discount, what does a specific pharmacy charge in cash, what does a specific insurance plan require as a copay, and what does Florida Medicaid's current preferred drug list say. Each of those has a different evidence source and a different rate of change, which is the organizing idea for the rest of this page.

Tresiba has no FDA-set retail price, and no regulator sets what a Florida pharmacy or insurer charges for it. What is established by federal law is that Medicare Part D caps out-of-pocket cost for covered insulins, including Tresiba when it appears on a plan's formulary, at $35 per month under the Inflation Reduction Act. [2] Florida Medicaid coverage, commercial insurer tier placement, and manufacturer discount-card terms are each set independently by that payer or company and change by plan year, so any specific dollar amount a patient encounters for those pathways needs to be confirmed against the current plan document or program page rather than assumed to still apply.

Why the list price is not what most people pay

Manufacturers publish a wholesale acquisition cost, sometimes called list price, for branded insulins. That figure is a starting point for rebate negotiations between the manufacturer, pharmacy benefit managers, and insurers, and it is rarely what a patient actually pays. A cash-pay patient using a pharmacy discount card, a commercially insured patient using a copay, and a Medicaid patient with a formulary exception can all end up paying very different amounts from that starting list price and from each other.

Because Novo Nordisk's wholesale acquisition cost and third-party discount-card pricing (GoodRx, RxSaver, pharmacy loyalty programs) change on their own schedules and vary by ZIP code and pharmacy chain, this page does not assert a specific current dollar figure for either. Readers should check the manufacturer's own pricing page and a discount-card comparison tool at the time of filling a prescription, since a number that was accurate at one point may not be current later.

Will Florida Medicaid cover Tresiba?

Florida Medicaid is administered through the Statewide Medicaid Managed Care program, and the Florida Agency for Health Care Administration (AHCA) maintains a preferred drug list that is updated on a recurring schedule. Whether Tresiba is preferred, requires prior authorization, or is excluded depends on the current version of that list and on the specific managed care plan a Medicaid enrollee is assigned to. This is exactly the kind of fact that changes between quarters and should be checked against AHCA's published preferred drug list rather than assumed from a prior year's experience.

In general, prior authorization for a non-preferred basal insulin typically requires the prescriber to document that preferred, formulary alternatives were considered or tried, and to describe a clinical reason (such as a documented pattern of hypoglycemia) for choosing a non-preferred agent instead. The American Diabetes Association's Standards of Care describes basal insulin selection as something that should account for patient-specific factors including hypoglycemia risk, which is the kind of guideline language a prior authorization request or appeal would typically cite. [3] This page does not reproduce a specific quoted passage from that document, since exact wording changes between annual editions; the current edition should be checked directly before citing specific language in a clinical appeal.

How commercial insurance usually handles Tresiba in Florida

Florida's major commercial carriers, including Florida Blue, UnitedHealthcare, Aetna, Cigna, and Humana, place branded basal insulins like Tresiba on a preferred or non-preferred brand tier, and prior authorization is common for type 2 diabetes indications specifically. The exact tier, copay amount, and prior authorization trigger vary by employer group and plan year, and a plan's own Summary of Benefits and Coverage document, checked at the start of a plan year or after any job or plan change, is the only reliable source for that patient's actual cost.

A practical point that does not depend on any specific plan: patients who change insurance during open enrollment should re-check Tresiba's tier on the new plan before assuming their prior copay still applies, since a tier change between plan years is common and can meaningfully change annual out-of-pocket cost.

Manufacturer assistance: what to verify before counting on it

Novo Nordisk has historically offered more than one type of patient support for its insulins, generally including a program that caps monthly out-of-pocket cost for eligible uninsured patients and a separate income-based patient assistance program that can provide medication at no cost to qualifying low-income, uninsured patients. Both types of programs typically exclude patients who have any form of government insurance (Medicare, Medicaid, TRICARE), which is a common source of confusion for Florida patients who carry both Medicare and a commercial supplement.

Because eligibility rules, income thresholds, and dollar caps for manufacturer programs change and are set entirely by the manufacturer, this page does not restate specific current thresholds. The manufacturer's own program page is the only reliable source for current eligibility criteria, and it should be checked at the time of enrollment rather than relied on from a prior year's terms.

Is compounded insulin degludec a legitimate option in Florida?

Compounded versions of FDA-approved drugs, including insulins, can be prepared by state-licensed 503A compounding pharmacies for individual patients with a valid prescription, under both state pharmacy board oversight and the federal framework the FDA describes for human drug compounding. [4] A 503A pharmacy compounds for an individual patient rather than producing commercial-scale batches, which is a different regulatory category from a 503B outsourcing facility.

Two things matter clinically here. First, a compounded product is not FDA-approved and has not undergone the same manufacturing and bioequivalence review as brand-name Tresiba, which is a real clinical consideration a prescriber should document and a patient should understand before choosing this route. Second, whether compounding insulin degludec specifically is currently permitted, and under what conditions, depends on the FDA's current bulk drug substance lists and on Florida Board of Pharmacy rules, both of which can change. A patient considering this option should confirm with the compounding pharmacy, and ideally with the prescriber, that the pharmacy holds a current Florida compounding permit and that the specific preparation is within current FDA and state guidance, rather than relying on a general statement that compounding "is legal."

Can a Florida telehealth visit lead to a Tresiba prescription?

Insulin is not a federally controlled substance, so the in-person evaluation requirements that apply to controlled-substance telehealth prescribing (under the Ryan Haight framework) do not apply to insulin. Florida law generally allows a licensed Florida physician or advanced practice registered nurse to establish a valid patient-provider relationship through a synchronous audio-video telehealth encounter and to prescribe non-controlled medications, including insulin, based on that encounter and supporting clinical information such as recent A1C and glucose values.

The specific statutory and licensing details (Florida's telehealth statute, provider registration requirements for out-of-state platforms) are legal facts that a patient or clinic should verify against the current Florida statute and Board of Medicine or Board of Nursing guidance rather than treat as static, since state telehealth rules have shifted meaningfully in recent years across many states.

How does Tresiba compare with cheaper basal insulin alternatives?

Most Florida Medicaid and commercial formularies prefer insulin glargine (as Lantus, Basaglar, or the U-300 formulation Toujeo) as first-line basal insulin, generally at a lower cash and formulary cost than Tresiba. The clinical argument for choosing degludec over glargine in an individual patient typically rests on two points reported in the literature: a lower observed rate of severe hypoglycemia in at least one large cardiovascular outcomes trial (DEVOTE) comparing degludec with glargine U-100 in people with type 2 diabetes, and a documented ability to vary the timing of the daily injection without needing to keep to a fixed 24-hour schedule. Readers and prescribers who want to cite the exact effect sizes from that trial, or from the dosing-flexibility study, should pull the original New England Journal of Medicine and Diabetes Care publications directly rather than relying on a secondhand number, since this page is not able to verify a specific cited statistic against the original paper with confidence.

Toujeo (glargine U-300) has a similarly long duration of action and a cash price that is often comparable to Tresiba's, so a prior authorization request that asks a plan to prefer degludec over Toujeo specifically should include a documented, patient-specific clinical reason rather than a general preference.

Monitoring basics (general information, not individualized dosing advice)

The FDA label for Tresiba describes typical starting doses and titration approaches for insulin-naive patients, and it states that Tresiba should not be diluted or mixed with other insulins in the same syringe or pen. [5] Patients using both a basal insulin like Tresiba and a separate rapid-acting insulin need two distinct injection devices. Actual starting dose, titration schedule, and target glucose range should come from the prescribing clinician for that specific patient; the label's general dosing framework is background information, not a substitute for an individualized regimen.

A1C is typically monitored more frequently during dose titration and less frequently once a patient's regimen is stable, consistent with general ADA guidance, and any patient whose glucose control worsens or who experiences recurrent low blood sugar, especially overnight, should contact their prescriber promptly rather than adjusting the dose independently. Signs of severe hypoglycemia (confusion, loss of consciousness, seizure) are a medical emergency requiring immediate care.

What is established, what is plausible, and what is not established

Established: Tresiba is FDA-approved as a basal insulin for glycemic control in adults and children with diabetes; it should not be mixed with other insulins in the same device; Medicare Part D's $35 monthly insulin cap is current federal law for covered insulins on a plan's formulary. [2][5]

Plausible but not something this page can verify with a specific number: the exact magnitude of degludec's hypoglycemia advantage over glargine U-100 from the DEVOTE trial, and the exact non-inferiority margin for flexible-interval dosing, both of which require checking the original trial publications directly.

Not established by any source available for this page: any specific current dollar amount for Novo Nordisk's list price, Florida retail cash price, a named commercial insurer's copay, or Florida Medicaid's current formulary status for Tresiba. These change on independent schedules and must be verified at the time of use.

Verification checklist: stable facts vs. facts you must re-check

Use this before relying on anything in this article or repeating it to a patient.

Stable, unlikely to change quickly (verify once against the primary source):

• FDA-approved indication, dosing form (U-100/U-200 FlexTouch), and "do not mix with other insulins" labeling instruction, check the current FDA label. [5]
• Insulin degludec's basic pharmacology (ultra-long-acting basal insulin, once-daily dosing), check the FDA label or NDA record. [5][6]
• The legal framework distinguishing 503A patient-specific compounding from 503B outsourcing-facility manufacturing, check FDA's compounding guidance. [4]
• The existence of a federal $35/month Medicare Part D insulin cap under the Inflation Reduction Act, check CMS or CDC policy pages. [2]

Date-sensitive, must be re-verified before quoting a number or coverage rule:

• Novo Nordisk's current wholesale list price for Tresiba
• Current cash/discount price at a specific Florida pharmacy chain or ZIP code
• Whether Tresiba is on Florida Medicaid's current AHCA preferred drug list, and for which diagnosis
• A specific commercial insurer's (Florida Blue, UnitedHealthcare, Aetna, Cigna, Humana) current tier placement and prior authorization criteria for the current plan year
• Current eligibility rules and dollar caps for any Novo Nordisk savings card or patient assistance program
• Whether a specific Florida compounding pharmacy currently holds an active state permit and whether insulin degludec is currently within FDA's permitted compounding scope
• Current Florida telehealth statute language and any provider registration requirement for out-of-state platforms

If any dosing information or guideline in this article differs from what a patient's insurance plan, pharmacy, or state agency currently specifies, the patient should follow their current plan or state requirements.

Common questions